The urinary tract infection market is expected to rise at a 3.5% CAGR and thus, reach a market valuation worth USD 11.3 billion by the end of the global forecast period in 2027.
A person having diabetes and further, contracting the urological health issues have a very close connection. Diabetes further creates health issues and increases the risk of contracting UTIs, alongside bladder issues. Also, diabetes can lead and result in a worsened condition of the problems like urologic issues and conditions. This is because, these are known to have an impact on the blood flow of an individual, the functions of the nerves and also affect the sensory functions that are performed by the body. A huge population that lives in different parts of the world is affected by diabetes health conditions. Also, this is further giving a rise to other commonly occurring issues like kidney stones and also, increased number of UTI cases being reported with each passing day. The patients who are suffering from similar illnesses are demanding treatment and drugs at a global scale and hence, this is likely to give a prominent rise to the urinary tract infection market by the end of the global forecast period in 2027.
Owing to these trends, increased infections, and the demand for drugs and treatment, the market report reflects a promising and increasing future for the market size. The urinary tract infection market is expected to rise at a 3.5% CAGR and thus, reach a market valuation worth USD 11.3 billion by the end of the global forecast period in 2027.
COVID 19 Analysis
Since the novel coronavirus is expanding its horizon and entering various industries, market verticals, businesses, and countries, researchers are on the way to have more knowledge and vaccine development for the treatment of different infection variants. Due to the adversity of the situation, the people are questioning the competence of the prevailing healthcare structure and thus, are demanding a well-equipped, updated, and technology-related infrastructure. Also, the spread of the pandemic has been very bad for the production and manufacturing units of businesses and companies. They have been forced to shut down because of their incapacity and incapability to live up to the urinary tract infection industry demands and production levels. Healthcare services, on the other hand, are experiencing a rise.
However, the healthcare professionals are employed in treating the patients who have contracted the coronavirus diseases, the ones who are suffering from other issues like diabetes and UTIs are having a hard time. So, the government is collaborating with the key market players regarding the investment decisions in the development of infrastructure that is based on high technology and also, caters to the demands in qualitative and efficient ways.
Urinary Tract Infection Market Dynamics
The key urinary tract infection market players are investing in the research and development departments for combining and launching more drugs that suit the needs of a global audience. For instance, FDA has superiority as a combination for treating patients who are suffering from a kidney infection. Hence, these will help the urinary tract infection market to grow as per the expectation during the forecast period.
Currently, the process of designing the antibacterial drugs and trials is an elaborated and complex procedure. Also, the absence of an ethical and scientific approach during these procedures is likely to restrain the market from growing as per the expectation during the assessment period.
The urinary tract infection market is opting for clinical trials for antibodies that belong to the therapeutic drugs categories. With due respect to the approach and the results presented after conducting the procedures, like trial design, interpretation, alongside the elaborated analysis. To approve the trials, it is better to design the drugs in a simple way that targets the enhancement of passing informative and ethical use. Also, the market players are likely to follow a scientific approach and developing steps to cater to similar requirements. Hence, the urinary tract infection market has a promising global forecast period that ends in 2027.
Urinary Tract Infections Market Share, By Type, 2019 (%)
Source: MRFR Analysis
Urinary Tract Infection Market Segment Overview
To discuss the urinary tract infection market growth, it is imperative to have an idea about the revenue cycle of the global market. The market has been bifurcated into segments that will help to understand the operations and revenue potential. This makes a difference to the investment decisions and market strategies taken up. The global market has been segmented based on the following heads:
The urinary tract infection deals in drugs like quinolones, aminoglycosides, azoles, alongside others like penicillin, and cephalosporins. Quinolones are further being segmented into enoxacin, pefloxacin, norfloxacin, alongside fleroxacin. In 2019, this was the highest growing sub-segment in the market.
The applications segment of the urinary tract infection includes cystitis, pyelonephritis, alongside urethritis, amongst others. Urethritis experienced the largest market share back in 2019.
This segment includes escherichia coli, klebsiella pneumonia, Proteus mirabilis, and others
Hospitals, healthcare centers, clinics, alongside the self-administered ones, are the market end-users of the urinary tract infection market.
Global Urinary Tract Infections Market Share, By Region, 2019 (%)
Source: MRFR Analysis
The North American market consisting of countries like the USA, and Canada, alongside Latin America. The North American market is expecting a steep increase in their investment towards innovation and technological advancements towards therapeutic products and diagnoses that will be helpful for the global growth of the urinary tract infection market. The USA has an increasingly global market share owing to the demand because of the rising prevalence of UTIs and kidney problems amongst the population of this region. The second-largest regional growth in terms of revenue is likely to be experienced by the European nations. The economic burden associated with the market is increasing in Europe. However, the fastest growth during the tenure is likely to be experienced by the APAC urinary tract infection market as the awareness is rising and people are getting education related to the same.
To draw a competitive graph amongst the key market players of the market and assess the revenue potential through the recent developments undertaken, it is important to have an idea of the functional urinary tract infection market players. They are as follows:
The global market report has been curated by considering the viewpoints as put forward by the industry experts and market leaders. Also, the report helps to have an idea about the market dynamics and insights of the market for better decisions. The report mentions the market segregation across various geographical regions and also, discusses the prominent urinary tract infection market players. The report also mentions the market’s recent developments.
|Market Size||USD 11.3 Billion|
|CAGR||3.5% (2020 - 2027)|
|Forecast Units||Value (USD Billion)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||By Drug Class, Application, End-User, Region|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Pfizer Inc., Teva Pharmaceuticals, Novo Nordisk A/S, GlaxoSmithKline plc, Bayer AG, Novartis Ag, Cipla Inc., Merck & Co., Inc., Eli Lily, Company, Allergan|
|Key Market Opportunities||Key market players are investing in the research and development departments for combining and launching more drugs|
|Key Market Drivers||superiority for treating patients who are suffering from a kidney infection|
The urinary tract infection (UTI) market would grow up to USD9.89 billion by 2023.
The urinary tract infection (UTI) market would grow with a 3.6% CAGR during the forecast period of 2018 to 2023.
North America would display strong market positioning among all the urinary tract infection (UTI) market players.
The US would trigger growth for the North American urinary tract infection (UTI) market.
The Asia Pacific would be the fastest in terms of growth among all the urinary tract infection (UTI) market players.